<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p96" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_96{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_96{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_96{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_96{left:341px;bottom:30px;}
#t5_96{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_96{left:377px;bottom:30px;}
#t7_96{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_96{left:540px;bottom:30px;}
#t9_96{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_96{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#tb_96{left:44px;bottom:63px;letter-spacing:0.1px;}
#tc_96{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_96{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_96{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_96{left:1123px;bottom:47px;letter-spacing:0.32px;}
#tg_96{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_96{left:36px;bottom:747px;letter-spacing:-0.1px;word-spacing:-0.32px;}
#ti_96{left:318px;bottom:747px;}
#tj_96{left:328px;bottom:747px;letter-spacing:-0.18px;word-spacing:0.03px;}
#tk_96{left:36px;bottom:728px;}
#tl_96{left:47px;bottom:728px;letter-spacing:-0.09px;}
#tm_96{left:47px;bottom:710px;letter-spacing:-0.12px;word-spacing:0.02px;}
#tn_96{left:47px;bottom:692px;letter-spacing:-0.09px;}
#to_96{left:36px;bottom:666px;}
#tp_96{left:47px;bottom:666px;letter-spacing:-0.11px;word-spacing:0.02px;}
#tq_96{left:47px;bottom:648px;letter-spacing:-0.1px;word-spacing:-0.02px;}
#tr_96{left:47px;bottom:630px;letter-spacing:-0.1px;}
#ts_96{left:1120px;bottom:637px;}
#tt_96{left:1132px;bottom:630px;letter-spacing:-0.09px;}
#tu_96{left:47px;bottom:611px;letter-spacing:-0.09px;}
#tv_96{left:664px;bottom:619px;}
#tw_96{left:677px;bottom:611px;letter-spacing:-0.09px;}
#tx_96{left:47px;bottom:593px;letter-spacing:-0.09px;}
#ty_96{left:36px;bottom:568px;letter-spacing:-0.09px;}
#tz_96{left:47px;bottom:550px;letter-spacing:-0.09px;}
#t10_96{left:47px;bottom:531px;letter-spacing:-0.09px;}
#t11_96{left:47px;bottom:513px;letter-spacing:-0.09px;}
#t12_96{left:326px;bottom:513px;}
#t13_96{left:341px;bottom:513px;letter-spacing:-0.08px;}
#t14_96{left:503px;bottom:520px;}
#t15_96{left:36px;bottom:488px;}
#t16_96{left:47px;bottom:488px;letter-spacing:-0.09px;}
#t17_96{left:47px;bottom:469px;letter-spacing:-0.09px;}
#t18_96{left:47px;bottom:451px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t19_96{left:36px;bottom:426px;letter-spacing:-0.09px;}
#t1a_96{left:47px;bottom:407px;letter-spacing:-0.09px;}
#t1b_96{left:613px;bottom:415px;}
#t1c_96{left:36px;bottom:382px;}
#t1d_96{left:47px;bottom:382px;letter-spacing:-0.09px;}
#t1e_96{left:36px;bottom:357px;letter-spacing:-0.09px;}
#t1f_96{left:47px;bottom:339px;letter-spacing:-0.1px;}
#t1g_96{left:496px;bottom:778px;letter-spacing:0.44px;word-spacing:-0.26px;}
#t1h_96{left:36px;bottom:215px;}
#t1i_96{left:46px;bottom:209px;letter-spacing:0.13px;word-spacing:-0.01px;}
#t1j_96{left:36px;bottom:198px;}
#t1k_96{left:46px;bottom:192px;letter-spacing:0.12px;word-spacing:0.01px;}
#t1l_96{left:45px;bottom:176px;letter-spacing:0.13px;}
#t1m_96{left:36px;bottom:165px;}
#t1n_96{left:46px;bottom:159px;letter-spacing:0.11px;word-spacing:-0.03px;}
#t1o_96{left:45px;bottom:142px;letter-spacing:0.13px;}
#t1p_96{left:36px;bottom:131px;}
#t1q_96{left:46px;bottom:125px;letter-spacing:0.12px;}
#t1r_96{left:45px;bottom:108px;letter-spacing:0.14px;}
#t1s_96{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_96{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_96{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_96{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_96{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_96{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_96{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_96{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.s7_96{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s8_96{font-size:17px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s9_96{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.sa_96{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sb_96{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts96" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg96Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg96" style="-webkit-user-select: none;"><object width="1210" height="935" data="96/96.svg" type="image/svg+xml" id="pdf96" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_96" class="t s0_96">NCCN Guidelines Version 4.2024 </span>
<span id="t2_96" class="t s0_96">Head and Neck Cancers </span>
<span id="t3_96" class="t s1_96">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_96" class="t s2_96">® </span>
<span id="t5_96" class="t s1_96">(NCCN </span>
<span id="t6_96" class="t s2_96">® </span>
<span id="t7_96" class="t s1_96">), All rights reserved. NCCN Guidelines </span>
<span id="t8_96" class="t s2_96">® </span>
<span id="t9_96" class="t s1_96">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_96" class="t s3_96">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="tb_96" class="t s3_96">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="tc_96" class="t s4_96">NCCN Guidelines Index </span>
<span id="td_96" class="t s4_96">Table of Contents </span>
<span id="te_96" class="t s4_96">Discussion </span>
<span id="tf_96" class="t s5_96">IMG-A </span>
<span id="tg_96" class="t s5_96">4 OF 4 </span>
<span id="th_96" class="t s5_96">Locoregionally Advanced Disease: </span><span id="ti_96" class="t s6_96">≥</span><span id="tj_96" class="t s5_96">6 Months to 5 Years Post-Treatment (Long-Term) </span>
<span id="tk_96" class="t s5_96">• </span><span id="tl_96" class="t s6_96" data-mappings='[[81,"fi"]]'>The majority of recurrences after treatment of head and neck cancer occur in the ﬁrst 2 years. Surveillance can be challenging because of </span>
<span id="tm_96" class="t s6_96" data-mappings='[[23,"fi"]]'>altered anatomy and/or ﬁbrosis from surgery, radiation, and/or chemotherapy. There are no consensus guidelines on the frequency and </span>
<span id="tn_96" class="t s5_96">modality of routine post-treatment imaging in the asymptomatic patient. Practice varies widely across institutions. </span>
<span id="to_96" class="t s5_96">• </span><span id="tp_96" class="t s6_96">US, CT, MRI, and PET/CT all have unique advantages and disadvantages when used as surveillance imaging. There is evidence that FDG- </span>
<span id="tq_96" class="t s5_96">PET/CT may be the most sensitive of these modalities. A 12-month PET has been shown to reveal recurrent or second primary cancers in </span>
<span id="tr_96" class="t s6_96" data-mappings='[[84,"fi"]]'>approximately 10% of treated patients; a 24-month FDG-PET/CT imaging revealed these ﬁndings in approximately 5% of treated cases. </span>
<span id="ts_96" class="t s7_96">4 </span>
<span id="tt_96" class="t s5_96">Most </span>
<span id="tu_96" class="t s5_96">cases of asymptomatic FDG-PET/CT lesion localization occur at distant sites. </span>
<span id="tv_96" class="t s7_96">7 </span>
<span id="tw_96" class="t s6_96" data-mappings='[[57,"fi"]]'>Whether earlier detection leads to improved disease-speciﬁc </span>
<span id="tx_96" class="t s5_96">survival is not established. </span>
<span id="ty_96" class="t s5_96">• Standardized multi-institutional imaging-based trials are needed to clearly elucidate the value of routine imaging in the clinically </span>
<span id="tz_96" class="t s6_96" data-mappings='[[53,"fi"]]'>asymptomatic patient. There may be little proven beneﬁt in further imaging if the initial 3-month FDG-PET/CT scan was negative. Ho et al </span>
<span id="t10_96" class="t s6_96" data-mappings='[[17,"fi"],[25,"ff"]]'>reported no signiﬁcant diﬀerence in 3-year disease-free survival in patients undergoing imaging surveillance versus those only receiving </span>
<span id="t11_96" class="t s5_96">clinical surveillance (41% vs. 46%, </span><span id="t12_96" class="t s8_96">P </span><span id="t13_96" class="t s5_96">= .91) in this setting. </span>
<span id="t14_96" class="t s7_96">8 </span>
<span id="t15_96" class="t s5_96">• </span><span id="t16_96" class="t s6_96" data-mappings='[[102,"fi"]]'>If an FDG-PET/CT at 3 months post-treatment is negative, there are no data to support substantial beneﬁt for further routine imaging in an </span>
<span id="t17_96" class="t s5_96">asymptomatic patient with negative exam. In the absence of multi-institutional prospective data, a tailored approach to surveillance with </span>
<span id="t18_96" class="t s5_96">attention to tumor type, stage, prognostic factors, symptomatology, and physical exam changes or restrictions is appropriate. </span>
<span id="t19_96" class="t s5_96">• US of the neck is a well-established tool for nodal surveillance. US is generally widely available, safe, fast, inexpensive, and an accurate </span>
<span id="t1a_96" class="t s5_96">modality for examination of the neck for any suspicious nodal disease. </span>
<span id="t1b_96" class="t s7_96">9 </span>
<span id="t1c_96" class="t s5_96">• </span><span id="t1d_96" class="t s6_96">Additional post-treatment imaging is indicated for worrisome or equivocal signs/symptoms. </span>
<span id="t1e_96" class="t s5_96">• Routine annual imaging (repeat use of pretreatment imaging modality) may be indicated to visualize areas inaccessible to routine clinical </span>
<span id="t1f_96" class="t s5_96">examination (deep-seated anatomic locations or areas obscured by extensive treatment change). </span>
<span id="t1g_96" class="t s5_96">PRINCIPLES OF IMAGING </span>
<span id="t1h_96" class="t s9_96">4 </span>
<span id="t1i_96" class="t sa_96">Heineman TE, Kuan EC, St John MA. When should surveillance imaging be performed after treatment for head and neck cancer? Laryngoscope 2017;127:533-534. </span>
<span id="t1j_96" class="t s9_96">7 </span>
<span id="t1k_96" class="t sa_96">Dunsky KA, Wehrmann DJ, Osman MM, et al. PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck </span>
<span id="t1l_96" class="t sa_96">cancer patient. Laryngoscope 2013;123:2161-2164. </span>
<span id="t1m_96" class="t s9_96">8 </span>
<span id="t1n_96" class="t sa_96">Ho AS, Tsao GJ, Chen FW, et al. Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer </span>
<span id="t1o_96" class="t sa_96">recurrence. Cancer 2013;19:1349-1356. </span>
<span id="t1p_96" class="t s9_96">9 </span>
<span id="t1q_96" class="t sa_96">Paleri V, Urbano TG, Mehanna H, et al. Management of neck metastases in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol </span>
<span id="t1r_96" class="t sa_96">Otol 2016;130:S161-S169. </span>
<span id="t1s_96" class="t sb_96">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
